SCHEMBL24011320

SCHEMBL24011320

COc1ccc(CNC(=O)NC2CCC(C(=O)N3CCN(Cc4ccncc4)CC3)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 4/20 0.61
▸ HRH3 Q9Y5N1 1/20 0.61
▸ NPC1 O15118 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ CYP3A4 P08684 2/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ LSS P48449 1/20 0.51
▸ DRD4 P21917 1/20 0.49
▸ EPHX1 P07099 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CYP2C9 P11712 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ SIGMAR1 Q99720 1/20 0.47
▸ MTNR1B P49286 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26633753 0.89 MCHR1 (0.54) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011262 0.88 MCHR1 (0.58) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011321 0.86 MCHR1 (0.53) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011294 0.85 SMN1; SMN2 (0.58) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011436 0.85 SMN1; SMN2 (0.63) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011437 0.85 SMN1; SMN2 (0.63) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL14456766 0.84 CYP3A4 (0.67) CYP3A4CYP2D6LSSCYP2C9TSHR
SCHEMBL24011390 0.83 SMN1; SMN2 (0.56) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011257 0.82 SMN1; SMN2 (0.65) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011062 0.82 SMN1; SMN2 (0.59) MCHR1HRH3NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
WO-2021226276-A2 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT MCHR1 360/4885HRH3 1432/4885NPC1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback